Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study

Jeffrey J. Bazarian, Peter Biberthaler, Robert D. Welch, Lawrence M. Lewis, Pal Barzo, Viktoria Bogner-Flatz, P. Gunnar Brolinson, Andras Büki, James Y. Chen, Robert H. Christenson, Dallas Hack, J. Stephen Huff, Sandeep Johar, J. Dedrick Jordan, Bernd A. Leidel, Tobias Lindner, Elizabeth Ludington, David O. Okonkwo, Joseph Ornato, W. Frank PeacockKara Schmidt, Joseph A. Tyndall, Arastoo Vossough, Andy S. Jagoda

Research output: Contribution to journalArticlepeer-review

318 Scopus citations

Abstract

Background: More than 50 million people worldwide sustain a traumatic brain injury (TBI) annually. Detection of intracranial injuries relies on head CT, which is overused and resource intensive. Blood-based brain biomarkers hold the potential to predict absence of intracranial injury and thus reduce unnecessary head CT scanning. We sought to validate a test combining ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), at predetermined cutoff values, to predict traumatic intracranial injuries on head CT scan acutely after TBI. Methods: This prospective, multicentre observational trial included adults (≥18 years) presenting to participating emergency departments with suspected, non-penetrating TBI and a Glasgow Coma Scale score of 9–15. Patients were eligible if they had undergone head CT as part of standard emergency care and blood collection within 12 h of injury. UCH-L1 and GFAP were measured in serum and analysed using prespecified cutoff values of 327 pg/mL and 22 pg/mL, respectively. UCH-L1 and GFAP assay results were combined into a single test result that was compared with head CT results. The primary study outcomes were the sensitivity and the negative predictive value (NPV) of the test result for the detection of traumatic intracranial injury on head CT. Findings: Between Dec 6, 2012, and March 20, 2014, 1977 patients were recruited, of whom 1959 had analysable data. 125 (6%) patients had CT-detected intracranial injuries and eight (<1%) had neurosurgically manageable injuries. 1288 (66%) patients had a positive UCH-L1 and GFAP test result and 671 (34%) had a negative test result. For detection of intracranial injury, the test had a sensitivity of 0·976 (95% CI 0·931–0·995) and an NPV of 0·996 (0·987–0·999). In three (<1%) of 1959 patients, the CT scan was positive when the test was negative. Interpretation: These results show the high sensitivity and NPV of the UCH-L1 and GFAP test. This supports its potential clinical role for ruling out the need for a CT scan among patients with TBI presenting at emergency departments in whom a head CT is felt to be clinically indicated. Future studies to determine the value added by this biomarker test to head CT clinical decision rules could be warranted. Funding: Banyan Biomarkers and US Army Medical Research and Materiel Command.

Original languageEnglish
Pages (from-to)782-789
Number of pages8
JournalThe Lancet Neurology
Volume17
Issue number9
DOIs
StatePublished - Sep 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study'. Together they form a unique fingerprint.

Cite this